{"nctId":"NCT01012973","briefTitle":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)","startDateStruct":{"date":"2009-10"},"conditions":["Retinal Vein Occlusion"],"count":177,"armGroups":[{"label":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","type":"EXPERIMENTAL","interventionNames":["Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","Other: Sham treatment"]},{"label":"Sham treatment","type":"SHAM_COMPARATOR","interventionNames":["Other: Sham treatment"]}],"interventions":[{"name":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","otherNames":[]},{"name":"Sham treatment","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Center-involved macular edema secondary to central retinal vein occlusion (CRVO) for no longer than 9 months with mean central subfield thickness ≥ 250 μm on optical coherence tomography (OCT)\n* Adults ≥ 18 years\n* Early treatment diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 to 24 letters) in the study eye\n\nExclusion Criteria:\n\n* Any prior treatment with anti-VEGF agents in the study eye (Pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc.) or previous administration of systemic anti-angiogenic medications\n* Prior panretinal laser photocoagulation or macular laser photocoagulation in the study eye\n* CRVO disease duration \\> 9 months from date of diagnosis\n* Previous use of intraocular corticosteroids in the study eye or use of periocular corticosteroids in the study eye within the 3 months prior to Day 1\n* Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or preretinal fibrosis involving the macula in either the study eye or fellow eye","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures","description":"Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \\* 100); Denominator = Number of participants analyzed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":null},{"groupId":"OG001","value":"22.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)","description":"Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. However, because this was assessed at the screening visit, subjects may have had a higher BCVA recorded at the baseline visit and would not have been excluded from the study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":"17.1"},{"groupId":"OG001","value":"54.3","spread":"20.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-448.58","spread":"256.02"},{"groupId":"OG001","value":"-169.27","spread":"224.72"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Developed Neovascularization During the First 24 Weeks","description":"Formation of blood vessels in the anterior segment, optic disc, or elsewhere in the fundus up to Week 24","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF","description":"The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.46","spread":"9.55"},{"groupId":"OG001","value":"3.55","spread":"9.74"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF","description":"EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.029","spread":"0.139"},{"groupId":"OG001","value":"-0.002","spread":"0.195"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":104},"commonTop":["Macular oedema","Nasopharyngitis","Retinal haemorrhage","Intraocular pressure increased","Conjunctival haemorrhage"]}}}